TRAW has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TRAW has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-26), Traws Pharma's share price is $0.6207. Traws Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Traws Pharma's Price-to-Owner-Earnings or its related term are showing as below:
As of today (2024-05-26), Traws Pharma's share price is $0.6207. Traws Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.87. Therefore, Traws Pharma's PE Ratio for today is At Loss.
As of today (2024-05-26), Traws Pharma's share price is $0.6207. Traws Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.87. Therefore, Traws Pharma's PE Ratio without NRI for today is At Loss.
The historical data trend for Traws Pharma's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
Traws Pharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Traws Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Traws Pharma's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Traws Pharma's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Traws Pharma's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 0.6207 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma (NAS:TRAW) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Traws Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Victor M Moyo | officer: CHIEF MEDICAL OFFICER | 12 PENNS TRAIL, NEWTOWN PA 18940 |
Trafford Clarke | director | 12 PENNS TRAIL, NEWTOWN PA 18940 |
Peter Atadja | director | 12 PENNS TRAIL, NEWTOWN PA 18940 |
Abraham N. Oler | officer: VP Corp Dev & Gen Counsel | C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052 |
Steven M Fruchtman | officer: Chief Medical Officer | 375 PHEASANT RUN, NEWTOWN PA 18940 |
James J Marino | director | C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940 |
Gelder Mark S. Md | officer: Chief Medical Officer | C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Mark Patrick Guerin | officer: Chief Accounting Officer | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Mary Teresa Shoemaker | director | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Michael B Hoffman | director | 1 GREENWICH OFFICE PARK, GREENWICH CT 06831 |
E Premkumar Reddy | director | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Jerome Groopman | director | C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922 |
Viren Mehta | director | OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747 |
Tyndall Capital Partners L P | 10 percent owner | 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.